THE SEVERE COURSE OF DRUG THERAPY-RESISTANT ANKYLOSING SPONDYLITIS

At present, there is more and more evidence in rheumatology on the factors influencing the efficacy of biological agents (BAs), and there is no generally accepted algorithm for managing patients resistant to standard therapy. The paper describes three patients with ankylosing spondylitis (AS) who we...

Full description

Saved in:
Bibliographic Details
Main Authors: D. G. Rumyantseva, M. V. Podryadnova, O. A. Rumyantseva, M. M. Urumova, Sh. Erdes
Format: Article
Language:Russian
Published: IMA PRESS LLC 2020-04-01
Series:Научно-практическая ревматология
Subjects:
Online Access:https://rsp.mediar-press.net/rsp/article/view/2882
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849243354395574272
author D. G. Rumyantseva
M. V. Podryadnova
O. A. Rumyantseva
M. M. Urumova
Sh. Erdes
author_facet D. G. Rumyantseva
M. V. Podryadnova
O. A. Rumyantseva
M. M. Urumova
Sh. Erdes
author_sort D. G. Rumyantseva
collection DOAJ
description At present, there is more and more evidence in rheumatology on the factors influencing the efficacy of biological agents (BAs), and there is no generally accepted algorithm for managing patients resistant to standard therapy. The paper describes three patients with ankylosing spondylitis (AS) who were followed up at the V.A. Nasonova Research Institute of Rheumatology in 2011–2019. All the patients showed a severe course of AS of high clinical and laboratory activities, extra-articular manifestations, and inefficacy of three or more BAs. All the patients share the following symptoms: male gender, early onset of disease, high clinical and laboratory activities, and extra-articular manifestations, such as uveitis and psoriasis.
format Article
id doaj-art-ea243decf0724a66a945f04dc906e17b
institution Kabale University
issn 1995-4484
1995-4492
language Russian
publishDate 2020-04-01
publisher IMA PRESS LLC
record_format Article
series Научно-практическая ревматология
spelling doaj-art-ea243decf0724a66a945f04dc906e17b2025-08-20T03:59:30ZrusIMA PRESS LLCНаучно-практическая ревматология1995-44841995-44922020-04-0158223223710.14412/1995-4484-2020-233-2372605THE SEVERE COURSE OF DRUG THERAPY-RESISTANT ANKYLOSING SPONDYLITISD. G. Rumyantseva0M. V. Podryadnova1O. A. Rumyantseva2M. M. Urumova3Sh. Erdes4V.A. Nasonova Research Institute of RheumatologyV.A. Nasonova Research Institute of RheumatologyV.A. Nasonova Research Institute of RheumatologyV.A. Nasonova Research Institute of RheumatologyV.A. Nasonova Research Institute of RheumatologyAt present, there is more and more evidence in rheumatology on the factors influencing the efficacy of biological agents (BAs), and there is no generally accepted algorithm for managing patients resistant to standard therapy. The paper describes three patients with ankylosing spondylitis (AS) who were followed up at the V.A. Nasonova Research Institute of Rheumatology in 2011–2019. All the patients showed a severe course of AS of high clinical and laboratory activities, extra-articular manifestations, and inefficacy of three or more BAs. All the patients share the following symptoms: male gender, early onset of disease, high clinical and laboratory activities, and extra-articular manifestations, such as uveitis and psoriasis.https://rsp.mediar-press.net/rsp/article/view/2882ankylosing spondylitisbiological agentshigh activityinefficacy of biological agents
spellingShingle D. G. Rumyantseva
M. V. Podryadnova
O. A. Rumyantseva
M. M. Urumova
Sh. Erdes
THE SEVERE COURSE OF DRUG THERAPY-RESISTANT ANKYLOSING SPONDYLITIS
Научно-практическая ревматология
ankylosing spondylitis
biological agents
high activity
inefficacy of biological agents
title THE SEVERE COURSE OF DRUG THERAPY-RESISTANT ANKYLOSING SPONDYLITIS
title_full THE SEVERE COURSE OF DRUG THERAPY-RESISTANT ANKYLOSING SPONDYLITIS
title_fullStr THE SEVERE COURSE OF DRUG THERAPY-RESISTANT ANKYLOSING SPONDYLITIS
title_full_unstemmed THE SEVERE COURSE OF DRUG THERAPY-RESISTANT ANKYLOSING SPONDYLITIS
title_short THE SEVERE COURSE OF DRUG THERAPY-RESISTANT ANKYLOSING SPONDYLITIS
title_sort severe course of drug therapy resistant ankylosing spondylitis
topic ankylosing spondylitis
biological agents
high activity
inefficacy of biological agents
url https://rsp.mediar-press.net/rsp/article/view/2882
work_keys_str_mv AT dgrumyantseva theseverecourseofdrugtherapyresistantankylosingspondylitis
AT mvpodryadnova theseverecourseofdrugtherapyresistantankylosingspondylitis
AT oarumyantseva theseverecourseofdrugtherapyresistantankylosingspondylitis
AT mmurumova theseverecourseofdrugtherapyresistantankylosingspondylitis
AT sherdes theseverecourseofdrugtherapyresistantankylosingspondylitis
AT dgrumyantseva severecourseofdrugtherapyresistantankylosingspondylitis
AT mvpodryadnova severecourseofdrugtherapyresistantankylosingspondylitis
AT oarumyantseva severecourseofdrugtherapyresistantankylosingspondylitis
AT mmurumova severecourseofdrugtherapyresistantankylosingspondylitis
AT sherdes severecourseofdrugtherapyresistantankylosingspondylitis